Logo image
Back
Abstract 11140: Mitral Valve Repair with the Mitraclip System in Patients with Cardiogenic Shock
Abstract   Peer reviewed

Abstract 11140: Mitral Valve Repair with the Mitraclip System in Patients with Cardiogenic Shock

Caleb Chiang, Konstantinos Voudris, Clifford J Kavinsky and Hussam Suradi
Circulation (New York, N.Y.), Vol.144(Suppl_1), pp.A11140-A11140
11/16/2021
DOI: 10.1161/circ.144.suppl_1.11140

View Online

Abstract

Introduction: The presence of significant mitral regurgitation (MR) in patients with cardiogenic shock (CS) patients is associated with worse prognoses. Limited data exists on the effect of percutaneous mitral valve repair (PMVR) with MitraClip in this population. Hypothesis: We examined short term outcomes of MitraClip PMVR in patients with CS and MR at 30 days and six months. Methods: Single-center, retrospective study of patients with CS and MR undergoing PMVR between January 2015 and December 2020. All patients were followed up for 6 months. Baseline and procedural characteristics as well as 30-day and six-months outcomes of all-cause mortality, heart failure hospitalizations, stroke, new atrial fibrillation, new pacemaker placement, and improvement in MR severity ≥2 grades were assessed. Results: A total of 20 patient were included for analysis. The mean age was 72.8 ± 11.1 years; 9 patients (45%) were men. MR was due to primary pathology in 9 patients (45%), functional in 2 (10%) and mixed in 9 (45%). Characteristics of the population are shown in Table 1. At 30 days all-cause mortality was 20% (n=4), while 2 patients (10%) required HF hospitalization. MR severity improved by at least 2 grades in 10 patients (50%). At six months, all-cause mortality was 40% (n=8), while 4 patients (20%) required heart failure readmission. 10 patients (50%) maintained the improvement in MR severity. There was no incidence of stroke, new atrial fibrillation, or new pacemaker placement at 30 days or 6 months. Conclusions: PMVR with the MitraClip system is a feasible and a safe option for MR in patients with CS. Improved MR severity is maintained at 30 days and 6 months.
 Mitral valve Shock, cardiogenic Mitral regurgitation

Details

Metrics

1 Record Views
Logo image